阿黴素全球市場 - 市場規模、佔有率、成長分析：按類型 - 產業預測（2023-2030 年）

Global Doxorubicin Market Size, Share, Growth Analysis, By Type(Conventional Doxorubicin formulation and liposomal Doxorubicin formulations) - Industry Forecast 2023-2030

出版日期: 2023年10月06日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計2021年全球阿黴素市場規模為9億美元，2022年將達11億美元。該市場預計到 2030 年將達到 17 億美元，在預測期內（2023-2030 年）年複合成長率為 5.8%。

全球阿黴素市場正在經歷顯著成長，預計將繼續保持上升趨勢。阿黴素是一種廣泛使用的化療藥物，用於治療多種癌症，主要是卵巢、卵巢癌、肺癌和軟組織肉瘤。該市場是由全球癌症罹患率不斷上升以及對有效癌症治療方案不斷成長的需求所推動的。此外，藥物輸送系統和聯合治療的進步進一步推動了市場的成長。然而，它也面臨著治療費用急劇上升、藥物副作用的可能性以及替代療法出現等挑戰。儘管存在這些挑戰，由於對個人化醫療和標靶治療的日益關注，阿黴素市場預計將在未來年度產生利潤豐厚的機會。

全球阿黴素市場的促進因素之一是全球癌症盛行率的不斷上升。阿黴素是一種化療藥物，廣泛用於治療多種癌症，包括乳癌、肺癌和白血病。癌症罹患率的上升和對有效癌症治療的需求不斷成長正在推動對阿黴素的需求。此外，探索阿黴素新適應症和配方的持續研究和開發也有助於市場成長。

全球阿黴素市場的抑制因素之一是其使用可能產生的副作用。已知阿黴素會引起各種副作用，包括心臟毒性、骨髓抑制和胃腸道疾病。這些副作用會限制其使用並對藥物給藥提出挑戰。醫療保健提供者應密切監測給藥阿黴素的患者，並採取必要的預防措施，以盡量減少和控制這些副作用。此外，在某些情況下，替代治療方案和標靶治療的出現也可能影響對阿黴素的需求。

該報告研究了全球多柔比星市場，並提供了市場概述，包括按類型、地區和參與市場的公司概況分類的趨勢。

主要企業簡介
- Pfizer
- Johnson & Johnson
- Teva Pharmaceutical Industries Ltd.
- Sanofi
- Novartis AG
- Sun Pharmaceutical Industries Ltd.
- Aspen Pharmacare Holdings Limited
- Baxter International Inc.
- Mylan NV
- Dr. Reddy's Laboratories Ltd.
- Cipla Limited
- Accord Healthcare Ltd
- Hikma Pharmaceuticals PLC
- Fresenius Kabi AG
- Kyowa Kirin Co., Ltd
- Takeda Pharmaceutical Company Limited
- Zydus Cadila
- Actavis Generics
- Wockhardt Ltd.
- Sandoz International GmbH

簡介目錄

Product Code: SQMIG35A2310

Global Doxorubicin Market size was valued at USD 0.9 billion in 2021 and is poised to grow from USD 1.1 billion in 2022 to USD 1.7 billion by 2030, growing at a CAGR of 5.8% in the forecast period (2023-2030).

The global doxorubicin market is experiencing significant growth and is expected to continue its upward trajectory in the coming years. Doxorubicin is a widely used chemotherapy drug that is primarily used in the treatment of various types of cancers, including breast cancer, ovarian cancer, lung cancer, and soft tissue sarcomas. The market is driven by the increasing prevalence of cancer worldwide and the growing demand for effective cancer treatment options. Additionally, advancements in drug delivery systems and combination therapies are further fueling the market growth. However, the market is also faced with challenges such as the high cost of treatment, potential side effects of the drug, and the emergence of alternative therapies. Despite these challenges, the increasing focus on personalized medicine and targeted therapies is expected to create lucrative opportunities for the Doxorubicin market in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Doxorubicin Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Doxorubicin Market Segmental Analysis

The global doxorubicin market is segmented by type and region. Based on type, the market can be segmented into conventional doxorubicin formulation and liposomal doxorubicin formulations. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Doxorubicin Market

Increasing Prevalence Of Cancer Worldwide

One driver of the global doxorubicin market is the increasing prevalence of cancer worldwide. Doxorubicin is a widely used chemotherapy drug for the treatment of various types of cancer, including breast cancer, lung cancer, and leukemia. The rising incidence of cancer cases, coupled with the growing need for effective cancer treatments, drives the demand for Doxorubicin. Additionally, ongoing research and development activities to explore new indications and formulations of Doxorubicin contribute to market growth.

Restraints in the Global Doxorubicin Market

Potential Side Effects Associated With Its Use

One restraint of the global doxorubicin market is the potential side effects associated with its use. Doxorubicin is known to cause various adverse effects, including cardiotoxicity, myelosuppression, and gastrointestinal issues. These side effects can limit its use and pose challenges in the administration of the drug. Healthcare providers need to carefully monitor patients receiving Doxorubicin and take necessary precautions to minimize and manage these side effects. Furthermore, the availability of alternative treatment options and the emergence of targeted therapies may also impact the demand for Doxorubicin in certain cases.

Market Trends of the Global Doxorubicin Key

One key market trend in the global doxorubicin market is the increasing adoption of combination therapies. Doxorubicin, a widely used chemotherapy drug, is often used in combination with other drugs or treatment modalities to enhance its effectiveness and reduce potential side effects. Combination therapies can help to overcome drug resistance, improve response rates, and increase overall survival rates for patients. Healthcare providers and researchers are exploring various combination regimens involving Doxorubicin, such as combining it with targeted therapies or immunotherapies, to achieve better treatment outcomes. This trend highlights the ongoing efforts to optimize Doxorubicin's therapeutic potential and improve the overall management of cancer patients.

Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
Drivers
Opportunities
Restraints
Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
Drivers
Opportunities
Restraints
Challenges
- Regulatory Landscape
- Porters Analysis
Competitive rivalry
Threat of Substitute Products
Bargaining Power of Buyers
Threat of New Entrants
Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
Political Impact
Economic Impact
Social Impact
Technical Impact
Environmental Impact
Legal Impact
Global Doxorubicin Market by Type
- Market Overview
- Conventional Doxorubicin formulation and liposomal Doxorubicin formulations
Global Doxorubicin Market Size by Region
- Market Overview
- North America
USA
Canada
- Europe
Germany
Spain
France
UK
Rest of Europe
- Asia Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
- Latin America
Brazil
Rest of Latin America
- Middle East & Africa (MEA)
GCC Countries
South Africa
Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
By Development
By Company
By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- Pfizer (United States)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Johnson & Johnson (United States)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Teva Pharmaceutical Industries Ltd. (Israel)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Sanofi (France)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Novartis AG (Switzerland)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Sun Pharmaceutical Industries Ltd. (India)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Aspen Pharmacare Holdings Limited (South Africa)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Baxter International Inc. (United States)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Mylan N.V. (United States)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Dr. Reddy's Laboratories Ltd. (India)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Cipla Limited (India)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Accord Healthcare Ltd. (United Kingdom)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Hikma Pharmaceuticals PLC (Jordan)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Fresenius Kabi AG (Germany)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Kyowa Kirin Co., Ltd. (Japan)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Takeda Pharmaceutical Company Limited (Japan)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Zydus Cadila (India)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Actavis Generics (United States)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Wockhardt Ltd. (India)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Sandoz International GmbH (Germany)
Company Overview
Business Segment Overview
Financial Updates
Key Developments